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Stroke prevention is the principal priority in the manage-ment of atrial fibrillation (AF); in the presence of stroke 
risk factors, oral anticoagulants (OACs) are recommended 
to reduce this risk, as well as all-cause mortality.1 Vitamin K 
antagonists (VKAs), such as warfarin, have been the standard 
OAC for several decades; however, an increased rate of major 
bleeding (MB) was observed in AF patients when compared 
with no anticoagulant treatment or placebo.2 In addition, war-
farin treatment has a narrow therapeutic range, drug and food 
interactions, the requirement of regular blood test monitoring 
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Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in Stroke: Observational Pooled 
Analysis on Health Outcomes and Experience of Patients) used multiple data sources to compare stroke/systemic 
embolism (SE) and major bleeding (MB) among a large number of nonvalvular atrial fibrillation patients on non–vitamin 
K antagonist oral anticoagulants (NOACs) or warfarin.
Methods—A retrospective observational study of nonvalvular atrial fibrillation patients initiating apixaban, dabigatran, 
rivaroxaban, or warfarin from January 1, 2013, to September 30, 2015, was conducted pooling Centers for Medicare and 
Medicaid Services Medicare data and 4 US commercial claims databases. After 1:1 NOAC-warfarin and NOAC-NOAC 
propensity score matching in each database, the resulting patient records were pooled. Cox models were used to evaluate 
the risk of stroke/SE and MB across matched cohorts.
Results—A total of 285 292 patients were included in the 6 matched cohorts: 57 929 apixaban-warfarin, 26 838 dabigatran-warfarin, 
83 007 rivaroxaban-warfarin, 27 096 apixaban-dabigatran, 62 619 apixaban-rivaroxaban, and 27 538 dabigatran-rivaroxaban 
patient pairs. Apixaban (hazard ratio [HR], 0.61; 95% CI, 0.54–0.69), dabigatran (HR, 0.80; 95% CI, 0.68–0.94), and rivaroxaban 
(HR, 0.75; 95% CI, 0.69–0.82) were associated with lower rates of stroke/SE compared with warfarin. Apixaban (HR, 0.58; 
95% CI, 0.54–0.62) and dabigatran (HR, 0.73; 95% CI, 0.66–0.81) had lower rates of MB, and rivaroxaban (HR, 1.07; 95% CI, 
1.02–1.13) had a higher rate of MB compared with warfarin. Differences exist in rates of stroke/SE and MB across NOACs.
Conclusions—In this largest observational study to date on NOACs and warfarin, the NOACs had lower rates of stroke/
SE and variable comparative rates of MB versus warfarin. The findings from this study may help inform the discussion 
on benefit and risk in the shared decision-making process for stroke prevention between healthcare providers and 
nonvalvular atrial fibrillation patients.
Clinical Trial Registration—URL: https://www.clinicaltrials.gov/. Unique identifier: NCT03087487.   (Stroke. 2018;49:2933-
2944. DOI: 10.1161/STROKEAHA.118.020232.)
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of the international normalized ratio, and frequent need for 
dose adjustment.3
In recent years, 4 non-VKA OACs (NOACs), dabigatran, 
rivaroxaban, apixaban, and edoxaban, have been approved 
for stroke prevention in AF based on their noninferiority in 
efficacy and safety compared with warfarin in randomized 
controlled trials (RCTs).4 In addition, no anticoagulation 
monitoring is required, and fewer drug and food interactions 
are evident.5 NOACs have changed the landscape of OAC use 
for stroke prevention in AF,6 but there are some pharmacolog-
ical differences among different NOACs, such as the mech-
anism of action, food effect, and renal clearance.5
There are no head-to-head clinical trials comparing the 
efficacy of NOACs versus other NOACs. However, indirect 
comparisons and network meta-analyses based on RCTs have 
demonstrated that NOACs have generally similar efficacy 
but varied safety profiles.7,8 Emerging observational studies 
have evaluated the effectiveness and safety among different 
NOACs in US clinical practice using single data sources, pro-
viding some evidence of the comparative effectiveness and 
safety between NOACs but with limited generalizability and 
a lack of a comprehensive evaluation on outcomes across var-
ious subgroups within nonvalvular AF (NVAF) patients.9,10
Using multiple data sources, this ARISTOPHANES study 
(Anticoagulants for Reduction in Stroke: Observational Pooled 
Analysis on Health Outcomes and Experience of Patients) com-
pared the rates of stroke/SE and MB and evaluated comparative 
rates across various subgroups among NVAF patients newly 
prescribed apixaban, dabigatran, rivaroxaban, or warfarin.
Methods
Data Sources
Authors will not be able to make their data available to other research-
ers because of restrictions specified in data licenses and data use 
agreements. However, the corresponding author is willing to share 
any nonproprietary information about analytical methods with any 
other researchers who want to reproduce the results or replicate the 
procedure if they have specific questions about the manuscript. This 
study was registered at URL: https://www.clincialtrials.gov (Unique 
identifier: NCT03087487).
Data in this study were pooled from the US Centers for Medicare 
and Medicaid Services Medicare data and 4 commercial claims data-
bases in the United States: the Truven MarketScan Commercial Claims 
and Encounter and Medicare Supplemental and Coordination of 
Benefits Database (MarketScan), the IMS PharMetrics Plus Database 
(PharMetrics), the Optum Clinformatics Data Mart (Optum), and the 
Humana Research Database (Humana)—which cover >180 million 
beneficiaries annually (≈56% of the US population).
Centers for Medicare and Medicaid Services Medicare data con-
tain medical and pharmacy claims from the 100% Medicare popu-
lation enrolled in Part A, Part B, and Part D programs (medical and 
pharmacy coverage). Detailed descriptions for the 5 data sets, ra-
tionale for the pooling process, and our approaches to minimize po-
tential patient record duplicates across data sources can be found in a 
previously published article and Document I in the online-only Data 
Supplement.11
Patient Selection
Patients with ≥1 pharmacy claim for apixaban, dabigatran, rivaroxa-
ban, or warfarin between January 1, 2013, and September 30, 2015, 
(identification period) were selected. The first NOAC pharmacy claim 
date during the identification period was designated as the index date 
for patients with any NOAC claim(s). For those without a NOAC 
claim, the first warfarin prescription date was designated as the index 
date. Patients were required to have an AF diagnosis on or before the 
index date and have continuous medical and pharmacy health plan 
enrollment for ≥12 months before the index date (baseline period).
Patients treated with any OAC within 12 months before the index 
date, with evidence of valvular heart disease, venous thromboem-
bolism, transient AF (pericarditis, hyperthyroidism, thyrotoxicity), 
or heart valve replacement/transplant during the baseline period, 
with pregnancy during the study period, or with hip or knee replace-
ment surgery within 6 weeks before the index date, were excluded. 
Additional exclusion criteria can be found in Figure I in the online-
only Data Supplement.
Outcome Measures
Outcome measures were time to first stroke/SE, including ischemic 
stroke, hemorrhagic stroke, and SE, and time to first MB, including 
gastrointestinal bleeding, intracranial hemorrhage, and MB at other 
key sites (Table I in the online-only Data Supplement).12,13 Outcomes 
were based on hospitalizations with stroke/SE or MB as the prin-
cipal or first-listed diagnosis. The follow-up period was from the day 
after the index date to 30 days after the discontinuation date, switch 
date, death (only inpatient death for the commercial databases and 
all-cause death for Medicare database), end of continuous medical 
or pharmacy plan enrollment, or the end of study period (September 
30, 2015), whichever occurred first. Additional details about patient 
selection and outcome measures can be found in Document I in the 
online-only Data Supplement.
Statistical Methods
One-to-one propensity score matching (PSM) was conducted be-
tween NOACs and warfarin (apixaban versus warfarin, dabigatran 
versus warfarin, and rivaroxaban versus warfarin) and between the 
NOACs (apixaban versus dabigatran, apixaban versus rivaroxaban, 
and dabigatran versus rivaroxaban). Patients were matched 1:1 in each 
data set based on the propensity scores generated by logistic regres-
sion based on demographics, Charlson Comorbidity Index score,14 
baseline bleeding and stroke/SE history, comorbidities, and baseline 
comedications (complete list of covariates in Table II in the online-
only Data Supplement). Nearest neighbor matching method without 
replacement with a caliper of 0.01 was used to match the patients.15 
The balance of covariates was checked based on standardized differ-
ences with a threshold of 10%.16 Study patients from the 5 datasets 
were pooled for analysis after ensuring cohorts were balanced.
After PSM, the rate of stroke/SE and MB in each PSM cohort was 
evaluated with Cox proportional hazard models with robust sandwich 
estimates.15 OAC treatment was included as the independent vari-
able, and no other covariates were included in the model because the 
cohorts were balanced.
Subgroup Analyses
Subgroup analyses were conducted for the following subgroups 
within the matched cohorts: age strata (<65, 65–74, 75–79, and ≥80 
years), sex, baseline CHA2DS2-VASc score (0–1, 2–3, and ≥4), base-
line HAS-BLED score (<3 and ≥3), congestive heart failure, coronary 
artery disease, peripheral arterial disease, diabetes mellitus, renal di-
sease, and prior stroke/SE. For the baseline CHA2DS2-VASc score 
subgroup, female patients without other stroke risk factors (ie, low 
risk) were assigned with a score of 0.17 In each subgroup, the balance 
of baseline characteristics between the treatment cohorts was evalu-
ated. When the standardized difference was >10%, the covariate was 
included in the Cox proportional hazards model. In each subgroup 
analysis, the statistical significance (P<0.10) of the interaction be-
tween treatment and the specific subgroup(s) was evaluated.
As another set of subgroup analysis, PSM and Cox models were 
reconducted to separately evaluate outcomes associated with each 
standard-dose NOAC (apixaban 5 mg, dabigatran 150 mg, rivaroxa-
ban 20 mg) and lower-dose NOAC (apixaban 2.5 mg, dabigatran 
75 mg, rivaroxaban 15 mg/10 mg) based on the index prescription 
dosage. Rematched cohorts included standard-dose NOAC versus 
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warfarin, lower-dose NOAC versus warfarin, standard-dose NOAC 
versus standard-dose NOAC, and lower-dose NOAC versus lower-
dose NOAC.
Sensitivity Analysis
Three sensitivity analyses were conducted. First, a sensitivity anal-
ysis was conducted by restricting the follow-up period to 1 year 
to help balance the follow-up period between the cohorts. Second, 
multivariate Cox proportional hazard models were conducted on all 
patients meeting the eligibility criteria (without PSM but with all 
covariates previously used for propensity score estimation alterna-
tively adjusted for in the Cox models). Third, we evaluated the rate of 
all-cause death for Medicare patients. In the Medicare data, death was 
obtained by validated Social Security records that include the date of 
death. The other databases do not include complete death informa-
tion, so mortality was only evaluated using the Centers for Medicare 
and Medicaid Services Medicare data.
Because the core study herein does not involve the collection, 
use, or transmittal of individual identifiable data, institutional review 
board approval is not required. Both the data sets and the security of 
the offices where analysis was completed (and where the data sets are 
kept) meet the requirements of the Health Insurance Portability and 
Accountability Act of 1996.
Results
After applying the selection criteria, a total of 321 182 NVAF 
patients were identified, including 63 484 apixaban, 27 571 
dabigatran, 103 477 rivaroxaban, and 126 650 warfarin patients 
(Figure I in the online-only Data Supplement). Before PSM, 
warfarin patients were the oldest and had the highest baseline 
CHA2DS2-VASc and HAS-BLED scores, followed by apixa-
ban, rivaroxaban, and dabigatran patients. For apixaban, dabi-
gatran, and rivaroxaban patients, 21% (2.5 mg), 15% (75 mg), 
and 24% (19% on 15 mg and 5% on 10 mg) had lower dosage 
regimens, respectively.
The unadjusted incidence rate of stroke/SE—including is-
chemic stroke, hemorrhagic stroke, and systemic embolism—
was 1.3 (apixaban), 1.5 (dabigatran), 1.4 (rivaroxaban), and 
2.2 (warfarin) per 100 person-years. The unadjusted incidence 
rate of MB was 3.5 (apixaban), 3.5 (dabigatran), 5.3 (rivaroxa-
ban), and 6.3 (warfarin) per 100 person-years (Table II in the 
online-only Data Supplement).
After PSM, a total of 285 292 unique patients were in-
cluded in the 6 matched cohorts: 57 929 apixaban-warfarin, 
26 838 dabigatran-warfarin, 83 007 rivaroxaban-warfarin, 
27 096 apixaban-dabigatran, 62 619 apixaban-rivaroxaban, 
and 27 538 dabigatran-rivaroxaban PSM pairs. Each cohort 
was matched separately; therefore, it is not appropriate to 
compare across the cohorts. The baseline characteristics of the 
matched populations are shown in Table 1 and Tables III and 
IV in the online-only Data Supplement.
NOAC-Warfarin and NOAC-NOAC Comparisons
The Kaplan-Meier curves for cumulative incidence rates of 
stroke/SE and MB in the matched populations are shown in 
Figure 1A and 1B.
Compared with warfarin, apixaban (hazard ratio [HR], 0.61; 
95% CI, 0.54–0.69), dabigatran (HR, 0.80; 95% CI, 0.68–0.94), 
and rivaroxaban (HR, 0.75; 95% CI, 0.69–0.82) were all asso-
ciated with lower rates of stroke/SE (Figure 2A). All NOACs 
were associated with lower rates of hemorrhagic stroke, whereas 
apixaban and rivaroxaban patients were associated with lower 
rates of ischemic stroke compared with warfarin.
Apixaban (HR, 0.58; 95% CI, 0.54–0.62) and dabigatran 
(HR, 0.73; 95% CI, 0.66–0.81) were associated with lower 
rates of MB compared with warfarin. Rivaroxaban (HR, 1.07; 
95% CI, 1.02–1.13) was associated with a higher rate of MB 
compared with warfarin. All 3 NOACs were associated with 
a lower rate of intracranial hemorrhage compared with war-
farin. Apixaban was associated with a lower rate (HR, 0.59; 
95% CI, 0.54–0.66), and rivaroxaban was associated with a 
higher rate (HR, 1.25; 95% CI, 1.16–1.34) of gastrointestinal 
bleeding compared with warfarin.
Apixaban was associated with a lower rate of stroke/SE 
and MB compared with dabigatran (stroke/SE—HR, 0.69; 
95% CI, 0.56–0.84; MB—HR, 0.77; 95% CI, 0.68–0.87) 
and rivaroxaban (stroke/SE—HR, 0.80; 95% CI, 0.71–0.91; 
MB—HR, 0.55; 95% CI, 0.51–0.59; Figure 2B). Dabigatran 
was associated with a lower rate of MB (HR, 0.70; 95% CI, 
0.63–0.77) compared with rivaroxaban, with similar rates of 
stroke/SE (HR, 1.15; 95% CI, 0.96–1.37).
Subgroup Analyses
The results of the subgroup analyses on age strata, sex, and 
baseline CHA2DS2-VASc score, HAS-BLED score, conges-
tive heart failure, coronary artery disease, peripheral arterial 
disease, diabetes mellitus, renal disease, and prior stroke/SE 
were generally consistent with the main results. A few signifi-
cant interactions were evident.
The magnitude of stroke/SE risk reduction for apixaban 
versus warfarin was greater in patients aged 75+ than those 
with aged <75 (Pint=0.049). Significant interaction was also 
found when evaluating the comparisons in MB for dabigatran 
and rivaroxaban versus warfarin across age/sex/CHA2DS2-
VASc score, with lower HRs observed in patients who were 
younger, male, and with lower baseline CHA2DS2-VASc 
scores (Figure 3A and 3B).
In the dose subgroup analysis, patients with lower- and 
standard-dose NOACs had very different baseline characteris-
tics (Tables V through X in the online-only Data Supplement). 
After PSM, both lower- and standard-dose patients showed 
broadly consistent results to the main analysis (Figure 3).
In the 2 sensitivity analyses, the results were generally 
consistent with the main analysis. When evaluating mortality 
in the Medicare population, all NOACs were associated with 
a lower rate of mortality compared with warfarin, and apixa-
ban was associated with a lower rate of mortality compared 
with dabigatran and rivaroxaban (Tables XI through XIII in 
the online-only Data Supplement).
Discussion
To our best knowledge, the ARISTOPHANES study is the larg-
est retrospective observational study to date examining the risk of 
stroke/SE and MB among NVAF patients who initiated NOAC 
treatment. By pooling the Centers for Medicare and Medicaid 
Services Medicare and 4 large US national claims data sets, this 
study demonstrated that apixaban, dabigatran, and rivaroxaban 
were associated with lower rates of stroke/SE compared with 
warfarin, and the safety results varied across NOACs.
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The results of this study add evidence to supplement 
results from clinical trials, where all the NOACs had non-
inferior rates of stroke/SE and MB compared with war-
farin.4,18–20 The results for apixaban versus warfarin were 
similar to the results of the ARISTOTLE trial (Apixaban for 
Reduction in Stroke and Other Thromboembolic Events in 
Atrial Fibrillation), wherein apixaban was superior to war-
farin in preventing stroke/SE and in reducing the risk of MB.20 
In the RE-LY trial (Randomized Evaluation of Long-Term 
Anticoagulation Therapy), dabigatran 150 mg was associated 
with a lower risk of stroke/SE and a similar risk of MB; in our 
study, we found that dabigatran was associated with a lower 
risk of both stroke/SE and MB.18 In the ROCKET-AF trial 
(Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition 
Compared With Vitamin K Antagonism for Prevention of 
Stroke and Embolism Trial in Atrial Fibrillation), rivaroxaban 
was noninferior for both stroke/SE and MB compared with 
warfarin; a significantly lower risk of stroke/SE was found for 
rivaroxaban versus warfarin in our study, and the difference 
in MB between rivaroxaban and warfarin reached statistical 
significance (with higher bleeding risk associated with rivar-
oxaban).19 The findings from this study may help inform the 
discussion of benefit and risk in the shared decision-making 
process for stroke prevention between healthcare providers 
and individual NVAF patients, when considering the balance 
between thromboembolic and bleeding risks.21
Table 1. Baseline Characteristics of Patients Prescribed Warfarin and NOACs After Propensity Score Matching Table 1. Continued
 
 
Apixaban (N=57 929) Warfarin (N=57 929) Dabigatran (N=26 838) Warfarin (N=26 838) Rivaroxaban (N=83 007) Warfarin (N=83 007) Apixaban (N=27 096) Dabigatran (N=27 096) Apixaban (N=62 619) Rivaroxaban (N=62 619) Dabigatran (N=27 538) Rivaroxaban (N=27 538)
Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/%
Age 74.3 74.2 71.9 72.0 74.4 74.4 71.7 71.6 73.1 72.9 71.4 71.4
  <65 17.5% 17.6% 23.6% 23.6% 14.9% 15.1% 24.9% 24.8% 22.3% 22.3% 25.4% 25.5%
  65–74 30.9% 31.0% 33.4% 34.0% 33.7% 33.6% 32.8% 32.8% 29.8% 30.3% 32.7% 32.3%
  75–79 18.1% 18.1% 17.9% 18.0% 19.4% 19.4% 17.4% 17.6% 17.1% 16.8% 17.4% 17.8%
  ≥80 33.5% 33.3% 25.1% 24.4% 32.0% 31.9% 24.9% 24.8% 30.7% 30.6% 24.5% 24.4%
Sex
  Male 54.1% 53.8% 58.8% 58.6% 55.1% 55.1% 59.3% 59.1% 55.2% 54.8% 59.5% 59.8%
  Female 45.9% 46.2% 41.2% 41.4% 44.9% 44.9% 40.7% 40.9% 44.8% 45.2% 40.5% 40.2%
Baseline comorbidity
  CHA
2
DS
2
-VASc Score 3.7 3.7 3.4 3.4 3.7 3.7 3.3 3.3 3.5 3.5 3.3 3.3
   0 3.6% 3.4% 5.4% 5.3% 2.9% 2.8% 5.9% 5.8% 4.5% 4.6% 6.0% 5.9%
   1 6.2% 6.1% 8.8% 8.8% 6.1% 5.6% 9.7% 9.6% 8.0% 8.5% 9.8% 10.1%
   2 14.5% 13.8% 16.9% 16.6% 14.6% 13.9% 17.3% 16.8% 15.8% 15.8% 17.0% 17.2%
   3 21.5% 22.0% 22.5% 22.8% 22.6% 23.5% 22.1% 22.2% 21.3% 21.2% 22.1% 21.7%
   4+ 54.2% 54.7% 46.3% 46.5% 53.8% 54.1% 45.0% 45.6% 50.5% 50.0% 45.1% 45.1%
  HAS-BLED score* 3.0 3.0 2.7 2.7 2.9 2.9 2.6 2.7 2.9 2.8 2.6 2.6
   0 2.9% 2.9% 4.5% 4.6% 2.5% 2.5% 4.7% 4.6% 3.4% 3.5% 4.9% 4.9%
   1 10.5% 10.6% 14.0% 14.0% 10.5% 10.4% 14.6% 14.4% 12.4% 12.7% 14.7% 14.8%
   2 25.3% 25.5% 29.1% 28.6% 26.7% 27.3% 29.3% 29.2% 26.0% 26.3% 29.2% 27.9%
   3+ 61.4% 61.0% 52.3% 52.7% 60.3% 59.8% 51.4% 51.7% 58.2% 57.5% 51.2% 52.4%
Congestive heart failure 28.5% 28.9% 24.5% 24.8% 27.8% 27.9% 23.6% 24.1% 26.6% 26.1% 23.9% 23.9%
Diabetes mellitus 34.8% 34.7% 35.0% 35.1% 35.8% 35.7% 33.6% 34.2% 33.5% 32.9% 34.4% 34.7%
Renal disease 23.0% 23.3% 16.2% 16.6% 20.4% 20.6% 16.1% 16.0% 20.9% 20.8% 15.8% 15.9%
Stroke/SE 12.1% 12.3% 10.1% 10.3% 11.7% 11.9% 9.7% 9.9% 11.2% 11.0% 9.8% 10.0%
Peripheral artery disease 19.3% 20.3% 15.6% 16.9% 19.0% 19.5% 15.6% 15.5% 18.1% 18.4% 15.3% 16.2%
Coronary artery disease 46.2% 45.5% 40.5% 39.7% 44.3% 44.1% 39.7% 40.1% 44.6% 43.5% 39.8% 39.8%
Dose of the index prescription 
  Standard dose† 77.5%  84.6%  72.1%  83.2% 84.8% 79.3% 73.3% 85.0% 76.7%
  Lower dose‡ 22.5%  15.4%  27.9%  16.8% 15.2% 20.7% 26.7% 15.0% 23.3%
Follow-up time, d 200.4 246.9 236.4 246.1 246.9 250.5 198.9 235.5 198.6 240.1 234.6 241.2
  Median 135 158 130 156 153 160 133 130 133 149 128 149
(Continued ) HAS-BLED indicates hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs and alcohol; INR, 
international normalized ratio; and NOAC, non–vitamin K antagonists oral anticoagulants.
*As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0–8.
†Standard dose: 5 mg Apixaban, 150 mg Dabigatran, 20 mg Rivaroxaban.
‡Lower dose: 2.5 mg Apixaban, 75 mg Dabigatran, 10 or 15 mg Rivaroxaban. 4510; 3239; and 1350 patients in rivaroxaban-warfarin, apixaban-rivaroxaban, and 
dabigatran-rivaroxaban cohorts received 10 mg rivaroxaban, respectively.
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Other retrospective observational studies comparing NOACs 
to warfarin have also been conducted using various US data 
sources.11,22–28 Systematic reviews and meta-analyses concluded 
that the comparative effectiveness and safety results in the real-
world studies are generally consistent with those in the RCTs: all 
the NOACs were associated with similar or lower rates of stroke/
SE and lower intracranial hemorrhage; apixaban was associated 
with lower rates of MB and gastrointestinal bleeding; dabigatran 
was associated with similar or lower rates of MB but similar or 
higher rates of gastrointestinal bleeding; and rivaroxaban was 
associated with similar rates of MB and similar or higher gastro-
intestinal bleeding compared with warfarin.29–33 Our findings are 
generally consistent with these results.
Using the large pooled ARISTOPHANES data set with 
more statistical power and improved generalizability com-
pared with previous literature, most of which used a single 
data source, this study showed consistent comparative effec-
tiveness and safety results between NOACs and warfarin with 
Table 1. Baseline Characteristics of Patients Prescribed Warfarin and NOACs After Propensity Score Matching Table 1. Continued
 
 
Apixaban (N=57 929) Warfarin (N=57 929) Dabigatran (N=26 838) Warfarin (N=26 838) Rivaroxaban (N=83 007) Warfarin (N=83 007) Apixaban (N=27 096) Dabigatran (N=27 096) Apixaban (N=62 619) Rivaroxaban (N=62 619) Dabigatran (N=27 538) Rivaroxaban (N=27 538)
Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/% Mean/%
Age 74.3 74.2 71.9 72.0 74.4 74.4 71.7 71.6 73.1 72.9 71.4 71.4
  <65 17.5% 17.6% 23.6% 23.6% 14.9% 15.1% 24.9% 24.8% 22.3% 22.3% 25.4% 25.5%
  65–74 30.9% 31.0% 33.4% 34.0% 33.7% 33.6% 32.8% 32.8% 29.8% 30.3% 32.7% 32.3%
  75–79 18.1% 18.1% 17.9% 18.0% 19.4% 19.4% 17.4% 17.6% 17.1% 16.8% 17.4% 17.8%
  ≥80 33.5% 33.3% 25.1% 24.4% 32.0% 31.9% 24.9% 24.8% 30.7% 30.6% 24.5% 24.4%
Sex
  Male 54.1% 53.8% 58.8% 58.6% 55.1% 55.1% 59.3% 59.1% 55.2% 54.8% 59.5% 59.8%
  Female 45.9% 46.2% 41.2% 41.4% 44.9% 44.9% 40.7% 40.9% 44.8% 45.2% 40.5% 40.2%
Baseline comorbidity
  CHA
2
DS
2
-VASc Score 3.7 3.7 3.4 3.4 3.7 3.7 3.3 3.3 3.5 3.5 3.3 3.3
   0 3.6% 3.4% 5.4% 5.3% 2.9% 2.8% 5.9% 5.8% 4.5% 4.6% 6.0% 5.9%
   1 6.2% 6.1% 8.8% 8.8% 6.1% 5.6% 9.7% 9.6% 8.0% 8.5% 9.8% 10.1%
   2 14.5% 13.8% 16.9% 16.6% 14.6% 13.9% 17.3% 16.8% 15.8% 15.8% 17.0% 17.2%
   3 21.5% 22.0% 22.5% 22.8% 22.6% 23.5% 22.1% 22.2% 21.3% 21.2% 22.1% 21.7%
   4+ 54.2% 54.7% 46.3% 46.5% 53.8% 54.1% 45.0% 45.6% 50.5% 50.0% 45.1% 45.1%
  HAS-BLED score* 3.0 3.0 2.7 2.7 2.9 2.9 2.6 2.7 2.9 2.8 2.6 2.6
   0 2.9% 2.9% 4.5% 4.6% 2.5% 2.5% 4.7% 4.6% 3.4% 3.5% 4.9% 4.9%
   1 10.5% 10.6% 14.0% 14.0% 10.5% 10.4% 14.6% 14.4% 12.4% 12.7% 14.7% 14.8%
   2 25.3% 25.5% 29.1% 28.6% 26.7% 27.3% 29.3% 29.2% 26.0% 26.3% 29.2% 27.9%
   3+ 61.4% 61.0% 52.3% 52.7% 60.3% 59.8% 51.4% 51.7% 58.2% 57.5% 51.2% 52.4%
Congestive heart failure 28.5% 28.9% 24.5% 24.8% 27.8% 27.9% 23.6% 24.1% 26.6% 26.1% 23.9% 23.9%
Diabetes mellitus 34.8% 34.7% 35.0% 35.1% 35.8% 35.7% 33.6% 34.2% 33.5% 32.9% 34.4% 34.7%
Renal disease 23.0% 23.3% 16.2% 16.6% 20.4% 20.6% 16.1% 16.0% 20.9% 20.8% 15.8% 15.9%
Stroke/SE 12.1% 12.3% 10.1% 10.3% 11.7% 11.9% 9.7% 9.9% 11.2% 11.0% 9.8% 10.0%
Peripheral artery disease 19.3% 20.3% 15.6% 16.9% 19.0% 19.5% 15.6% 15.5% 18.1% 18.4% 15.3% 16.2%
Coronary artery disease 46.2% 45.5% 40.5% 39.7% 44.3% 44.1% 39.7% 40.1% 44.6% 43.5% 39.8% 39.8%
Dose of the index prescription 
  Standard dose† 77.5%  84.6%  72.1%  83.2% 84.8% 79.3% 73.3% 85.0% 76.7%
  Lower dose‡ 22.5%  15.4%  27.9%  16.8% 15.2% 20.7% 26.7% 15.0% 23.3%
Follow-up time, d 200.4 246.9 236.4 246.1 246.9 250.5 198.9 235.5 198.6 240.1 234.6 241.2
  Median 135 158 130 156 153 160 133 130 133 149 128 149
(Continued ) HAS-BLED indicates hypertension, abnormal renal and liver function, stroke, bleeding, labile international normalized ratio, elderly, drugs and alcohol; INR, 
international normalized ratio; and NOAC, non–vitamin K antagonists oral anticoagulants.
*As the INR value is not available in the databases, a modified HAS-BLED score was calculated with a range of 0–8.
†Standard dose: 5 mg Apixaban, 150 mg Dabigatran, 20 mg Rivaroxaban.
‡Lower dose: 2.5 mg Apixaban, 75 mg Dabigatran, 10 or 15 mg Rivaroxaban. 4510; 3239; and 1350 patients in rivaroxaban-warfarin, apixaban-rivaroxaban, and 
dabigatran-rivaroxaban cohorts received 10 mg rivaroxaban, respectively.
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Figure 1. Kaplan-Meier curves for stroke/SE and major bleeding. A, Cumulative incidence of stroke/systemic embolism (SE) and major bleeding in non–
vitamin K antagonist oral anticoagulant (NOAC)-warfarin propensity score–matched cohorts. B, Cumulative incidence of Stroke/SE and major bleeding in 
NOAC-NOAC propensity score–matched cohorts.
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previous studies. For example, this analysis had more statis-
tical power in evaluating less frequent events (eg, intracranial 
hemorrhage) and subgroups with limited sample size in RCTs 
(eg, peripheral arterial disease). Indeed, our subgroup analy-
ses provide supplemental information of the comparative ef-
fectiveness and safety among OACs stratifying by patient’s 
demographics, risk scores, and comorbidities, which showed 
generally consistent results with the main analysis.
Limitations
This retrospective observational study has several limita-
tions. First, our study is subject to the inherent limitations 
Figure 2. Comparison of stroke/SE and major bleeding between OACs. A, Incidence rates and hazard ratios of stroke/systemic embolism (SE) and major 
bleeding for non–vitamin K antagonist oral anticoagulants (NOACs) vs warfarin propensity score–matched cohorts. B, Incidence rates and hazard ratios of 
stroke/SE and major bleeding for NOACs vs NOACs propensity score–matched cohorts. GI indicates gastrointestinal; and ICH, intracranial hemorrhage.
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Figure 3. Subgroup analysis. A, Propensity score–matched hazard ratios of stroke/systemic embolism (SE) for non–vitamin K antagonist oral anticoagu-
lant (NOAC)-warfarin comparisons. †Age was included in the model because it was not balanced after propensity score matching (PSM) for apixaban and 
warfarin patients with prior stroke and for dabigatran and warfarin patients with renal disease. ‡Charlson Comorbidity Index (CCI) and anemia and coag-
ulation defects were included in the model because they were not balanced after PSM between 75 mg dabigatran and warfarin patients. B, Propensity 
score–matched hazard ratios of major bleeding for NOAC-warfarin comparisons. †Age was included in the model because it was not balanced after PSM for 
apixaban and warfarin patients with prior stroke and for dabigatran and warfarin patients with renal disease. ‡CCI and anemia and coagulation defects were 
included in the model because they were not balanced after PSM between 75 mg dabigatran and warfarin patients. (Continued )
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Figure 3 Continued.  C, Propensity score–matched hazard ratios of stroke/SE for NOAC-NOAC comparisons. D, Propensity score–matched hazard ratios 
of major bleeding for NOAC-NOAC comparisons. *Significant interactions were found (whether treatment effect was statistically different across subgroups). 
CAD indicates coronary artery disease; CHF, congestive heart failure; HAS-BLED, hypertension, abnormal renal and liver function, stroke, bleeding, labile in-
ternational normalized ratio, elderly, drugs and alcohol; and PAD, peripheral artery disease.
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of retrospective evaluations using healthcare claims data. 
Only statistical association rather than causal relation-
ships could be concluded. Although cohorts were matched 
through PSM, potential residual confounders exist. In clin-
ical practice, patients who receive different OACs may be 
systematically different, and to the extent that such differ-
ences are unobserved, study results may be biased. Other 
unmeasurable factors including differences in physician-
level, practice-level, and health plan-level characteristics 
may also confound the estimated association between medi-
cation exposure (individual OAC) and outcomes (stroke/SE 
and MB). This limitation is especially important for inter-
preting NOAC versus NOAC comparison results, which are 
for hypothesis generation given the lack of head-to-head 
trials. From an exploratory power calculation conducted 
by authors based on indirect treatment comparison of piv-
otal RCTs, nearly 27 000 patients would be needed to eval-
uate stroke/SE and MB outcomes across the 3 NOACs in a 
hypothetical head-to-head trial (assuming a 90% power). 
Second, because of the nature of claims studies, outcome 
measures were based on International Classification of 
Diseases, Ninth Revision, Clinical Modification codes 
without further adjudication using precise clinical criteria 
or further validation against healthcare providers’ med-
ical records. No evaluation of the dose reduction criteria 
for NOACs was allowed without comprehensive data on 
body weight or serum creatinine/creatinine clearance. In 
addition, laboratory values, such as international normal-
ized ratio measurements, are not available in the data set 
so we are unable to determine time in therapeutic range 
for patients prescribed warfarin. Nonetheless, by including 
patients with potentially poorer quality control of warfarin 
in everyday clinical practice, the findings of this study may 
better reflect real-world situations. Many clinically impor-
tant outcomes (eg, mild to moderate bleeding) associated 
with OAC use were not evaluated in the study because they 
cannot be reliably measured in claims databases. We relied 
on prescription dispense records to characterize OAC drug 
exposure, but patients’ actual drug taking behaviors can-
not be measured. Observed and unobserved heterogeneity 
may exist across the 5 data sources. However, published 
NOAC studies using those data sources have reported gen-
erally consistent findings.11,24,27,28 Finally, the results may 
not be generalizable to the overall NVAF population in the 
United States because the study did not include uninsured 
patients and patients solely covered by other public health 
insurance plans.
Some literature has proposed hypotheses on potential dif-
ferences in clinical outcomes between patients with different 
NOAC treatment based on existing pharmacological differ-
ences across NOACs (Table 2). A pharmacokinetics and phar-
macodynamics study suggested that once-daily dosing may 
potentially increase absolute patient adherence, but twice-daily 
dosing regimens may be more forgiving among patients with 
suboptimal adherence because of lower peak level and higher 
trough level of drug concentration.34 Rivaroxaban should be 
taken together with an evening meal, as this increases bioa-
vailability.35,36 In a recent US real-world study, about one-third 
of rivaroxaban users did not take rivaroxaban with an adequate 
meal.37 Apixaban and dabigatran do not demonstrate the same 
degree of food effect. However, no study has formally tested 
the causal relationship between pharmacological difference 
and clinical outcomes.
Please note that our NOAC versus NOAC compari-
sons are for hypotheses generating only. Those results 
should be interpreted with caution and need to be con-
firmed by findings from NOAC versus NOAC RCTs which 
are expected to be released in the upcoming years (eg, 
DARING-AF trial [Comparison of Efficacy and Safety 
Among Dabigatran, Rivaroxaban, and Apixaban in Non-
Valvular Atrial Fibrillation; URL: https://www.clinical-
trials.gov. Unique identifier: NCT02666157] in Taiwan 
and DANNOAC-AF trial [The Danish Non-Vitamin 
K Antagonist Oral Anticoagulation Study: A Cluster 
Randomized Study Comparing Safety and Efficacy of 
Edoxaban, Apixaban, Rivaroxaban and Dabigatran for 
Table 2. Clinical Pharmacology of Oral Anticoagulants
 Warfarin Dabigatran Rivaroxaban Apixaban Edoxaban
Mechanism of action Inhibitor of vitamin 
K–dependent factors
Direct thrombin 
inhibitor
Direct factor Xa inhibitor Direct factor Xa 
inhibitor
Direct factor Xa 
inhibitor
Oral bioavailability >95% ≈6.5% 80%–100% ≈50% ≈62%
Pro-drug No Yes No No No
Food effect Yes (foods high in 
vitamin K)
No Yes (20 mg and 15 mg 
doses need to be taken 
with food)
No No
Renal clearance Metabolized in liver, and 
excreted in urine mainly 
as metabolites
85% ≈33%* ≈27% 50%
Mean half-life (t
1/2
) 40 h 14–18 h† 5–9 h (young) 12 h 10–14 h
11–13 h (elderly)
T
max
72–96 h 0.5–2 h 2–4 h 3–4 h 1–2 h
OACs indicates oral anticoagulants; PI, prescribing information; and T
max
, time to reach peak plasma concentration.
*Direct renal excretion as unchanged active substance.
†Prolonged in patients with impaired renal function, licensed for patients up to moderate renal impairment.
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Oral Anticoagulation in Atrial Fibrillation; URL: https://
www.clinicaltrials.gov. Unique identifier: NCT03129490] 
in Denmark).38,39
Conclusions
In the largest observational study of NOAC use to date, 
we show that NOACs had lower rates of stroke/SE and 
variable comparative rates of MB versus warfarin. A com-
prehensive set of subgroup analyses in this study provide 
further evidence in the important subgroups of NVAF 
patients.
Sources of Funding
This study was funded by Pfizer Inc and Bristol-Myers Squibb.
Disclosures
A. Keshishian is a paid employee of STATinMED Research which 
is a paid consultant to Pfizer and Bristol-Myers Squibb. Dr Li, M. 
Hamilton, Dr Gupta, K. Friend, X. Pan, and Dr Nadkarni are paid 
employees of Bristol-Myers Squibb with ownership of stocks in 
Bristol-Myers Squibb. Drs Masseria, Luo, and Mardekian are paid 
employees of Pfizer Inc with ownership of stocks in Pfizer Inc. Dr 
Lip is a consultant for Bayer/Janssen, Merck, Sanofi, Bristol-Myers 
Squibb Company/Pfizer Inc, Daiichi-Sankyo, Biotronik, Medtronic, 
Portola, Novartis, Verseon, and Boehringer Ingelheim and has been 
on the speakers’ bureau for Bayer, Bristol-Myers Squibb Company/
Pfizer Inc, Boehringer Ingelheim, Daiichi-Sankyo, and Medtronic. Dr 
Deitelzweig is a consultant for Bayer/Janssen, Bristol-Myers Squibb 
Company/Pfizer Inc, Daiichi-Sankyo, Portola, and Boehringer 
Ingelheim and has been on the speakers’ bureau for Janssen, Bristol-
Myers Squibb Company/Pfizer Inc, and Boehringer Ingelheim. Dr 
Lip, A. Keshishian, Dr Li, M. Hamilton, Dr Masseria, Dr Gupta, Dr 
Luo, Dr Friend, Dr Nadkarni, and Dr Deitelzweig contributed to con-
ceptualize or design the work. A. Keshishian, Dr Li, X. Pan, and Dr 
Baser contributed to acquire the data for the work. A. Keshishian, 
Dr Mardekian, and X. Pan contributed to analyze the data for the 
work. All authors contributed to interpret the data for the work. A. 
Keshishian, Dr Li, Dr Luo, and Dr Friend drafted the work. All authors 
critically revised for important intellectual content. All authors finally 
approved the version to be published. All authors agreed to be ac-
countable for all aspects of the work in ensuring that questions related 
to the accuracy or integrity of any part of the work are appropriately 
investigated and resolved.
References
 1. Lip G, Freedman B, De Caterina R, Potpara TS. Stroke prevention in 
atrial fibrillation: past, present and future. Comparing the guidelines and 
practical decision-making. Thromb Haemost. 2017;117:1230–1239. doi: 
10.1160/TH16-11-0876
 2. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy 
to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann 
Intern Med. 2007;146:857–867.
 3. De Caterina R, Husted S, Wallentin L, Andreotti F, Arnesen H, 
Bachmann F, et al. Vitamin K antagonists in heart disease: current status 
and perspectives (Section III). Position paper of the ESC Working Group 
on Thrombosis–Task Force on Anticoagulants in Heart Disease. Thromb 
Haemost. 2013;110:1087–1107. doi: 10.1160/TH13-06-0443
 4. Ruff CT, Giugliano RP, Braunwald E, Hoffman EB, Deenadayalu N, 
Ezekowitz MD, et al. Comparison of the efficacy and safety of new 
oral anticoagulants with warfarin in patients with atrial fibrillation: a 
meta-analysis of randomised trials. Lancet. 2014;383:955–962. doi: 
10.1016/S0140-6736(13)62343-0
 5. Nutescu E, Chuatrisorn I, Hellenbart E. Drug and dietary interac-
tions of warfarin and novel oral anticoagulants: an update. J Thromb 
Thrombolysis. 2011;31:326–343. doi: 10.1007/s11239-011-0561-1
 6. Mazurek M, Huisman MV, Rothman KJ, Paquette M, Teutsch C, Diener 
HC, et al; GLORIA-AF Investigators. Regional differences in antithrom-
botic treatment for atrial fibrillation: insights from the GLORIA-AF 
Phase II Registry. Thromb Haemost. 2017;117:2376–2388. doi: 
10.1160/TH17-08-0555
 7. Cameron C, Coyle D, Richter T, Kelly S, Gauthier K, Steiner S, et 
al. Systematic review and network meta-analysis comparing anti-
thrombotic agents for the prevention of stroke and major bleeding 
in patients with atrial fibrillation. BMJ Open. 2014;4:e004301. doi: 
10.1136/bmjopen-2013-004301
 8. López-López JA, Sterne JAC, Thom HHZ, Higgins JPT, Hingorani AD, 
Okoli GN, et al. Oral anticoagulants for prevention of stroke in atrial 
fibrillation: systematic review, network meta-analysis, and cost effective-
ness analysis. BMJ. 2017;359:j5058.
 9. Noseworthy PA, Yao X, Abraham NS, Sangaralingham LR, McBane 
RD, Shah ND. Direct comparison of dabigatran, rivaroxaban, and apixa-
ban for effectiveness and safety in nonvalvular atrial fibrillation. Chest. 
2016;150:1302–1312. doi: 10.1016/j.chest.2016.07.013
 10. Graham DJ, Reichman ME, Wernecke M, Hsueh YH, Izem R, 
Southworth MR, et al. Stroke, bleeding, and mortality risks in elderly 
Medicare beneficiaries treated with dabigatran or rivaroxaban for non-
valvular atrial fibrillation. JAMA Intern Med. 2016;176:1662–1671. doi: 
10.1001/jamainternmed.2016.5954
 11. Li XS, Deitelzweig S, Keshishian A, Hamilton M, Horblyuk R, Gupta 
K, et al. Effectiveness and safety of apixaban versus warfarin in non-
valvular atrial fibrillation patients in “real-world” clinical practice. 
A propensity-matched analysis of 76,940 patients. Thromb Haemost. 
2017;117:1072–1082. doi: 10.1160/TH17-01-0068
 12. Thigpen JL, Dillon C, Forster KB, Henault L, Quinn EK, Tripodis Y, 
et al. Validity of international classification of disease codes to identify 
ischemic stroke and intracranial hemorrhage among individuals with as-
sociated diagnosis of atrial fibrillation. Circ Cardiovasc Qual Outcomes. 
2015;8:8–14. doi: 10.1161/CIRCOUTCOMES.113.000371
 13. Cunningham A, Stein CM, Chung CP, Daugherty JR, Smalley WE, Ray 
WA. An automated database case definition for serious bleeding related 
to oral anticoagulant use. Pharmacoepidemiol Drug Saf. 2011;20:560–
566. doi: 10.1002/pds.2109
 14. Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of 
classifying prognostic comorbidity in longitudinal studies: development 
and validation. J Chronic Dis. 1987;40:373–383.
 15. Austin PC. The use of propensity score methods with survival or time-to-
event outcomes: reporting measures of effect similar to those used in random-
ized experiments. Stat Med. 2014;33:1242–1258. doi: 10.1002/sim.5984
 16. Austin PC. Balance diagnostics for comparing the distribution of base-
line covariates between treatment groups in propensity-score matched 
samples. Stat Med. 2009;28:3083–3107. doi: 10.1002/sim.3697
 17. Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, et al; 
ESC Scientific Document Group. 2016 ESC Guidelines for the manage-
ment of atrial fibrillation developed in collaboration with EACTS. Eur 
Heart J. 2016;37:2893–2962. doi: 10.1093/eurheartj/ehw210
 18. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh 
A, et al; RE-LY Steering Committee and Investigators. Dabigatran 
versus warfarin in patients with atrial fibrillation. N Engl J Med. 
2009;361:1139–1151. doi: 10.1056/NEJMoa0905561
 19. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al; 
ROCKET AF Investigators. Rivaroxaban versus warfarin in non-
valvular atrial fibrillation. N Engl J Med. 2011;365:883–891. doi: 
10.1056/NEJMoa1009638
 20. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna 
M, et al; ARISTOTLE Committees and Investigators. Apixaban versus 
warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–
992. doi: 10.1056/NEJMoa1107039
 21. Nielsen PB, Skjøth F. A two-sided evaluation of benefit and harm from 
antithrombotic treatment in atrial fibrillation: balancing clinical applica-
tion and statistical methodology. Thromb Haemost. 2016;116:405–406. 
doi: 10.1160/TH16-07-0523
 22. Yao X, Abraham NS, Sangaralingham LR, Bellolio MF, McBane RD, 
Shah ND, et al. Effectiveness and safety of dabigatran, rivaroxaban, and 
apixaban versus warfarin in nonvalvular atrial fibrillation. J Am Heart 
Assoc. 2016;5:e003725.
 23. Villines TC, Schnee J, Fraeman K, Siu K, Reynolds MW, Collins J, et al. 
A comparison of the safety and effectiveness of dabigatran and warfarin 
in non-valvular atrial fibrillation patients in a large healthcare system. 
Thromb Haemost. 2015;114:1290–1298. doi: 10.1160/TH15-06-0453
 24. Amin A, Keshishian A, Trocio J, Dina O, Le H, Rosenblatt L, et al. 
Risk of stroke/systemic embolism, major bleeding and associated 
costs in non-valvular atrial fibrillation patients who initiated apixaban, 
dabigatran or rivaroxaban compared with warfarin in the United States 
2944  Stroke  December 2018
Medicare population. Curr Med Res Opin. 2017;33:1595–1604. doi: 
10.1080/03007995.2017.1345729
 25. Hernandez I, Zhang Y, Saba S. Comparison of the effectiveness and 
safety of apixaban, dabigatran, rivaroxaban, and warfarin in newly 
diagnosed atrial fibrillation. Am J Cardiol. 2017;120:1813–1819. doi: 
10.1016/j.amjcard.2017.07.092
 26. Coleman CI, Antz M, Bowrin K, Evers T, Simard EP, Bonnemeier H, et 
al. Real-world evidence of stroke prevention in patients with nonvalvular 
atrial fibrillation in the United States: the REVISIT-US study. Curr Med 
Res Opin. 2016;32:2047–2053. doi: 10.1080/03007995.2016.1237937
 27. Seeger JD, Bykov K, Bartels DB, Huybrechts K, Zint K, Schneeweiss 
S. Safety and effectiveness of dabigatran and warfarin in routine care of 
patients with atrial fibrillation. Thromb Haemost. 2015;114:1277–1289. 
doi: 10.1160/TH15-06-0497
 28. Graham DJ, Reichman ME, Wernecke M, Zhang R, Southworth MR, 
Levenson M, et al. Cardiovascular, bleeding, and mortality risks in 
elderly Medicare patients treated with dabigatran or warfarin for 
nonvalvular atrial fibrillation. Circulation. 2015;131:157–164. doi: 
10.1161/CIRCULATIONAHA.114.012061
 29. Ntaios G, Papavasileiou V, Makaritsis K, Vemmos K, Michel P, Lip 
GYH. Real-world setting comparison of nonvitamin-K antagonist 
oral anticoagulants versus vitamin-K antagonists for stroke preven-
tion in atrial fibrillation: a systematic review and meta-analysis. Stroke. 
2017;48:2494–2503. doi: 10.1161/STROKEAHA.117.017549
 30. Deitelzweig S, Farmer C, Luo X, Vo L, Li X, Hamilton M, et al. Risk 
of major bleeding in patients with non-valvular atrial fibrillation 
treated with oral anticoagulants: a systematic review of real-world ob-
servational studies. Curr Med Res Opin. 2017;33:1583–1594. doi: 
10.1080/03007995.2017.1347090
 31. Bai Y, Shi XB, Ma CS, Lip GYH. Meta-analysis of effective-
ness and safety of oral anticoagulants in atrial fibrillation with 
focus on apixaban. Am J Cardiol. 2017;120:1689–1695. doi: 
10.1016/j.amjcard.2017.07.072
 32. Bai Y, Deng H, Shantsila A, Lip GY. Rivaroxaban versus dabigatran or 
warfarin in real-world studies of stroke prevention in atrial fibrillation: 
systematic review and meta-analysis. Stroke. 2017;48:970–976. doi: 
10.1161/STROKEAHA.116.016275
 33. Carmo J, Moscoso Costa F, Ferreira J, Mendes M. Dabigatran in real-
world atrial fibrillation. Meta-analysis of observational comparison stud-
ies with vitamin K antagonists. Thromb Haemost. 2016;116:754–763. 
doi: 10.1160/TH16-03-0203
 34. Vrijens B, Heidbuchel H. Non-vitamin K antagonist oral anticoagu-
lants: considerations on once- vs. twice-daily regimens and their poten-
tial impact on medication adherence. Europace. 2015;17:514–523. doi: 
10.1093/europace/euu311
 35. Stampfuss J, Kubitza D, Becka M, Mueck W. The effect of food on the 
absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol 
Ther. 2013;51:549–561. doi: 10.5414/CP201812
 36. Rivaroxaban- Food and Drug Administration, Prescribing 
Information. 2011. http://www.accessdata.fda.gov/drugsatfda_docs/
label/2014/022406s009lbl.pdf. Accessed May 8, 2018.
 37. Packard KA, Leiter M, Qi Y, et al. Evaluation of rivaroxaban administra-
tion for atrial fibrillation in a cardiology practice. JACC. 2018;17:333.
 38. Tainan Municipal Hospital, E-DA Hospital, National Cheng-Kung 
University Hospital Dou-Liou Branch, Ministry of Health and Welfare, 
Taiwan. Comparison of Efficacy and Safety Among Dabigatran, Rivaroxaban, 
Apixaban, Non-Valvular Atrial Fibrillation (DARING-AF). 2016. https://
clinicaltrials.gov/ct2/show/NCT02666157. Accessed July 25, 2018.
 39. Danish Heart Foundation. Danish Society of Cardiology. The Danish 
Non-Vitamin K Antagonist Oral Anticoagulation Study in Patients With 
Atrial Fibrillation (DANNOAC-AF). 2017. https://clinicaltrials.gov/ct2/
show/NCT03129490. Accessed July 25, 2018.
